Investors of Hims & Hers Health, Inc. Granted Opportunity to Lead Class Action Lawsuit Amid Significant Losses

Hims & Hers Health, Inc. Class Action Lawsuit Overview

Robbins Geller Rudman & Dowd LLP has recently announced an important opportunity for investors in Hims & Hers Health, Inc. (NYSE: HIMS) to participate in a class action lawsuit. If you purchased or acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, you could be eligible to lead this significant case. The deadline for seeking appointment as lead plaintiff is August 25, 2025.

Background of the Case

The lawsuit, filed under the title Sookdeo v. Hims & Hers Health, Inc., charges the company and its executives with violations under the Securities Exchange Act of 1934. Investors who have experienced substantial financial losses during the class period should consider their potential role in this collective legal action.

According to the filed complaint, on April 29, 2025, Hims & Hers announced a collaboration with Novo Nordisk A/S, promoting the sale of the FDA-approved drug, Wegovy®, through their platform. However, the complaint alleges troubling practices on the part of Hims & Hers, indicating that the company engaged in the misleading promotion of illegitimate versions of Wegovy® that jeopardized patient safety.

The details of the complaint are concerning. Not only did the lawsuit allege deceptive actions by Hims & Hers, but it also pointed to a significant risk that the partnership with Novo Nordisk was in jeopardy due to these actions. On June 23, 2025, as a direct consequence of these revelations, Novo Nordisk announced the termination of its partnership with Hims & Hers, causing the latter's stock to plummet over 34%.

The Role of a Lead Plaintiff

The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Hims & Hers securities during the specified class period to seek appointment as a lead plaintiff. This individual, ideally possessing the greatest financial interest in the relief sought, serves as the representative for all other class members in the lawsuit, guiding its direction in collaboration with the chosen attorneys.

Being appointed as a lead plaintiff is a crucial role, but it is important to note that other investors can still participate in the lawsuit without holding this title and may share in any potential recoveries.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP is recognized as a top-tier law firm specializing in securities fraud and shareholder litigation. The firm has gained notoriety for its exemplary track record, securing over $2.5 billion for investors in 2024 alone across numerous securities class action cases. With a dedicated team of approximately 200 lawyers working out of 10 offices, they are one of the largest plaintiffs' firms globally and have garnered many significant recoveries over the years.

In conclusion, for investors of Hims & Hers Health, Inc. experiencing considerable losses, this is an essential moment to engage in legal action. Those interested in leading the class action are encouraged to act swiftly. For more information on how to proceed, potential plaintiffs can contact Robbins Geller's attorneys or follow the link provided within the announcement for further details.

For more precise inquiries, you can reach attorneys J.C. Sanchez or Jennifer N. Caringal at Robbins Geller through phone or email as detailed above. It's crucial not to miss out on this significant opportunity for justice.